Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Weekly Report Card

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Jul 11, 2021 12:47pm

142 Views

Post# 33527787

RE:RE:RE:RE:RE:RE:Weekly Report Card

First I am not in a position to fight anything. I am just tired of seeing this board taken over by this subject. I explained my view here many times. I think most of this situation is out of the management's hands. No promotion or propaganda will change the actual perception of the company. Only very clear positive and meaningful hard facts would change that quickly, and the phase I in oncology is the only hope that it could happen and there are many reasons to think that it could happen, but until it happens, nothing is sure. We have to wait and look out for any positive signs we can detect ahead of the real results. But as I said here many times, the more the time is going by without a news, the better it is.